Sandoz Secures Global License for Breast Cancer Biosimilar

Sandoz Group AG has announced a global license agreement with EirGenix Inc. This grants Sandoz the exclusive rights to commercialize a biosimilar for pertuzumab, used in treating HER2-positive early and metastatic breast cancer. The reference medicine market for pertuzumab is valued at USD 4.1 billion in global sales.

The agreement, worth up to USD 152 million, includes an upfront payment and potential market performance incentives. Sandoz aims to strengthen its oncology portfolio by complementing its existing biosimilars trastuzumab and trastuzumab deruxtecan. Sandoz's global commercialization rights exclude certain Asian countries.

Sandoz is focused on providing affordable medicines, enhancing patient access, and supporting healthcare systems. With this agreement, Sandoz reinforces its biosimilar offerings, aiming to address the needs of millions affected by breast cancer annually.